Every 8-K that Nutriband (NTRBW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NTRBW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTRBW filings page.
Nutriband Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026. The revolving line replaces a prior $5,000,000 facility that had been scheduled to expire on July 13, 2026 and carries interest at 7% per annum on drawdowns.
The lender cannot convert amounts outstanding under the credit line into common stock, so this financing remains straight debt rather than potential equity dilution. The company states that the facility is intended to provide funding through the FDA approval process and into commercial-scale manufacturing for its patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. reported recent exercises of its outstanding stock options and warrants for the period from February 1 through July 31, 2025. Holders exercised stock options covering 20,055 shares of common stock for a total exercise price of $44,206.
During the same period, holders of the company’s publicly traded warrants (trading under symbol NTRBW) exercised warrants to purchase 47,076 shares of common stock for a total purchase price of $302,699. In addition, private investors exercised warrants to purchase 778,041 shares of common stock, generating a total exercise price of $5,002,804.
Form 8-K highlights
On 5 Aug 2025 Nutriband (Nasdaq: NTRB) completed a stock dividend of 3,008,643 Series A Convertible Preferred shares, issuing one preferred share for every four common shares held as of 25 Jul 2025 (fractions rounded down). The distribution is treated as an unregistered sale under Item 3.02.
Item 5.03 notes that the board, without shareholder vote, amended the Articles of Incorporation on 9 Jul 2025 to create the Series A non-voting preferred class (par $0.001). Authorised shares were first set at 2.79 m and later increased to 10 m via a Certificate of Correction filed 21 Jul 2025.
The preferred shares will convert 1-for-1 into common stock only after FDA approval of AVERSA-based transdermal products. Until conversion eligibility and SEC/Nasdaq registration are complete, the shares are restricted and held by transfer agent Equiniti. Holders may receive dividends declared on either preferred or common stock. Exhibits 3.1D and 3.1E contain the charter amendment and correction.